氯喹用于马拉维妊娠期疟疾预防的随机对照试验
在马拉维布兰太尔开展开放标签单中心随机对照试验,纳入900名HIV阴性孕妇,比较间歇性磺胺多辛-乙胺嘧啶、间歇性氯喹和氯喹每周预防的疗效。主要终点胎盘疟疾在改良意向治疗人群中未显示氯喹优于磺胺多辛-乙胺嘧啶,但协议指定调整分析中氯喹预防组胎盘感染降低34%。
要点
- 间歇性氯喹未改善胎盘疟疾保护,与间歇性磺胺多辛-乙胺嘧啶相当。
- 氯喹每周预防在调整分析中与胎盘感染降低34%相关,需更大样本验证。
- 间歇性氯喹组母体贫血和不良事件更多,但严重不良事件罕见。
核心结论
- 在高磺胺多辛-乙胺嘧啶耐药地区,间歇性氯喹未提供优于间歇性磺胺多辛-乙胺嘧啶的疟疾保护。
- 氯喹每周预防可能有助于预防妊娠期疟疾,但需更大样本研究确认。
研究设计与样本
- 开放标签、单中心、随机对照试验,在马拉维南部布兰太尔Ndirande健康中心进行。
- 纳入900名孕20-28周、HIV阴性的初产或二次妊娠孕妇,按1:1:1随机分配。
- 主要分析为改良意向治疗人群,共765名有胎盘组织病理学数据的参与者。
主要发现
- 胎盘疟疾总体患病率为14%(108/765),低于预期。
临床怎么用
- 当前证据不支持将间歇性氯喹作为替代间歇性磺胺多辛-乙胺嘧啶的妊娠期疟疾预防方案。
- 氯喹每周预防的潜在益处需权衡不良事件风险,并等待更大样本研究确认。
局限性
- 单中心开放标签设计,可能引入偏倚。
- 胎盘疟疾实际患病率低于预期,可能影响统计效能。
- 主要分析人群排除了无胎盘病理数据的参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sulfadoxine-pyrimethamine resistance threatens efficacy of intermittent preventive treatment of malaria during pregnancy, and alternative regimens need to be identified. With the return of chloroquine efficacy in southern Africa, we postulated that chloroquine either as an intermittent therapy or as weekly chemoprophylaxis would be more efficacious than intermittent sulfadoxine-pyrimethamine for prevention of malaria in pregnancy and associated maternal and newborn adverse outcomes. METHODS: We did an open-label, single-centre, randomised controlled trial at Ndirande Health Centre, Blantyre, in southern Malawi. We enrolled pregnant women (first or second pregnancy) at 20-28 weeks' gestation who were HIV negative. Participants were randomly assigned in a 1:1:1 ratio using a computer-generated list to either intermittent sulfadoxine-pyrimethamine (two doses of 1500 mg sulfadoxine and 75 mg pyrimethamine, 4 weeks apart), intermittent chloroquine (two doses of 600 mg on day 1, 600 mg on day 2, and 300 mg on day 3), or chloroquine prophylaxis (600 mg on day 1 then 300 mg every week). The primary endpoint was placental malaria in the modified intent-to-treat population, which consisted of participants who contributed placental histopathology data at birth. Secondary outcomes included clinical malaria, maternal anaemia, low birthweight, and safety. This trial is registered with ClinicalTrials.gov, number NCT01443130. FINDINGS: Between February, 2012, and May, 2014, we enrolled and randomly allocated 900 women, of whom 765 contributed histopathological data and were included in the primary analysis. 108 (14%) women had placental malaria, which was lower than the anticipated prevalence of placental malaria infection. Protection from placental malaria was not improved by chloroquine as either prophylaxis (30 [12%] of 259 had positive histopathology; relative risk [RR] 0·75, 95% CI 0·48-1·17) or intermittent therapy (39 [15%] of 253; RR 1·00, 0·67-1·50) compared with intermittent sulfadoxine-pyrimethamine (39 [15%] of 253). In protocol-specified analyses adjusted for maternal age, gestational age at enrolment, bednet use the night before enrolment, anaemia at enrolment, and malaria infection at enrolment, women taking chloroquine as prophylaxis had 34% lower placental infections than did those allocated intermittent sulfadoxine-pyrimethamine (RR 0·66, 95% CI 0·46-0·95). Clinical malaria was reported in nine women assigned intermittent sulfadoxine-pyrimethamine, four allocated intermittent chloroquine (p=0·26), and two allocated chloroquine prophylaxis (p=0·063). Maternal anaemia was noted in five women assigned intermittent sulfadoxine-pyrimethamine, 15 allocated intermittent chloroquine (p=0·038), and six assigned chloroquine prophylaxis (p>0·99). Low birthweight was recorded for 31 babies born to women allocated intermittent sulfadoxine-pyrimethamine, 29 assigned intermittent chloroquine (p=0·78), and 41 allocated chloroquine prophylaxis (p=0·28). Four women assigned intermittent sulfadoxine-pyrimethamine had adverse events possibly related to study product compared with 94 women allocated intermittent chloroquine (p<0·0001) and 26 allocated chloroquine prophylaxis (p<0·0001). Three women had severe or life-threatening adverse events related to study product, of whom all were assigned intermittent chloroquine (p=0·25). INTERPRETATION: Chloroquine administered as intermittent therapy did not provide better protection from malaria and related adverse effects compared with intermittent sulfadoxine-pyrimethamine in a setting of high resistance to sulfadoxine-pyrimethamine. Chloroquine chemoprophylaxis might provide benefit in protecting against malaria during pregnancy, but studies with larger sample sizes are needed to confirm these results. FUNDING: US National Institutes of Health.
引用
- Divala TH, Mungwira RG, Mawindo PM, et al. Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. Lancet Infect Dis. 2018. PMID: 30195996. doi:10.1016/S1473-3099(18)30415-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。